-
05
2023
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
The study is expected to complete in Q2 2024, and the topline results are anticipated in Q3 2024.
-
05
2023
Caliway Has Been Featured In Clinical Trial Arena Pipeline Moves
Clinical Trial Arena: May 2nd Pipeline Moves - Completion of Phase IIa non-malignant disorder trial
-
04
2023
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in a Phase 2-Stage 2 Study Evaluating the Efficacy of CBL-514 in Treating Moderate to Severe Cellulite
The subject recruitment and treatment in CBL-0201EFP Phase 2-Stage 1 is completed.
